Reference
Health Canada. MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis. Internet Document : 22 Jun 2020. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73387a-eng.php
Rights and permissions
About this article
Cite this article
Alemtuzumab linked with serious and potentially fatal ADRs. Reactions Weekly 1811, 1 (2020). https://doi.org/10.1007/s40278-020-80224-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-80224-2